Peer-Review ReportVisual Complications After Stent-Assisted Endovascular Embolization of Paraophthalmic and Suprasellar Variant Superior Hypophyseal Aneurysms: The Duke Cerebrovascular Center Experience in 57 Patients
Introduction
Aneurysms of the ophthalmic segment of the internal carotid artery (ICA) are diverse in their anatomic site of origin and spatial orientation with 20% of lesions having no named branch directly associated with the aneurysm neck (5, 23). This diversity has led to numerous terms and classification systems for surgical and angiographic purposes, creating significant confusion (5). The two dominant types of aneurysms that arise from this segment are named for their associated vessel: the ophthalmic or superior hypophyseal artery (23).
The ophthalmic artery arises from the anterior or anteromedial aspect of the ICA immediately after it traverses the distal dural ring and enters the subarachnoid space (1, 3, 5, 8, 11, 14, 26). The optic nerve is intimately associated with the ophthalmic artery, coursing just superior and medial to the ophthalmic origin as it proceeds toward the optic canal. Paraophthalmic aneurysms typically arise at the distal aspect of the ophthalmic origin and point superior or superomedially, and with progressive enlargement, their anatomic proximity to the optic apparatus may lead to visual disturbances (5). Visual field loss may be seen from compressive or ischemic optic neuropathy, or diplopia may be evident from oculomotor nerve compression (21).
Superior hypophyseal aneurysms arise along one of several perforating branches from the medial or inferomedial wall of the ICA. They may extend ventrally and burrow beneath the clinoid process (paraclinoid variant) or project medially beneath and elevate the optic chiasm (suprasellar variant) (5). The suprasellar variant may produce an ipsilateral or bitemporal visual field deficit similar to a pituitary tumor; however, the paraclinoid variant is unlikely to result in visual abnormalities even when the aneurysms become quite large. In a surgical series of 39 superior hypophyseal aneurysms reported by Day (5) in 1990, no paraclinoid variant superior hypophyseal aneurysm caused visual disturbances.
The intimate relationship between the optic nerve and ophthalmic artery makes surgical exposure and clipping of paraophthalmic aneurysms challenging. Complete exposure often requires removal of the clinoid process and dissection of the dural ring to identify the aneurysm neck completely (5). During surgery, visual loss can be caused by direct vascular injury, manipulation of the optic nerve, thermogenic effects from high-speed drilling of the clinoid, or other unknown causes (9, 10, 12, 15, 18).
Endovascular techniques for intracranial aneurysms, with their own unique but equally threatening list of possible complications, have been increasingly employed over the past 2 decades. With specific regard to paraclinoid aneurysms, coil embolization does not prevent possible visual complications. Acute and delayed visual deficits after endovascular treatment of paraophthalmic aneurysms have previously been described (21, 22, 25). In the acute setting, the deficit is typically related to mass effect on the optic apparatus or loss of the ophthalmic artery; delayed deficits are attributed to either progressive mass effect or perianeurysmal inflammation (25). Delayed effects have been reported 35 days after embolization (25).
The use of stent assistance has increased further the number of aneurysms that can be treated endovascularly, and this is true for paraophthalmic aneurysms. Given the wide neck configuration of these aneurysms as the typical indication for stent placement, it is reasonable to assume that the neck of these aneurysms more often incorporates the origin of the ophthalmic artery, which could be impacted and occluded by the coil mass. In addition, the stent itself may cover the ophthalmic artery origin resulting in retinal ischemia or thromboembolic complications. It has been reported that stent-assisted coiling results in improved coil packing (2, 20). Hypothetically, this improved packing may result in increased mass affect on the optic apparatus in paraophthalmic aneurysms or the chiasm in suprasellar variant superior hypophyseal aneurysms. We investigated the outcome and visual complication rate of stent-assisted coil embolization of paraophthalmic or suprasellar variant superior hypophyseal aneurysms.
Section snippets
Methods
After obtaining institutional review board approval, a retrospective review of the Duke Cerebrovascular Center database was performed to identify all patients for whom the Neuroform Microdelivery Stent System (Boston Scientific Corp., Natick, Massachusetts, USA) was successfully deployed for stent-assisted embolization of aneurysms of the ICA from November 2002 until October 2009. Angiograms obtained before and after embolization were reviewed by two of the authors (A.S.F. and T.P.S.) to
Patients
The database contained 112 patients with a stent placed in the ICA for embolization of at least one intracranial aneurysm. After review of the catheter angiograms, we identified 57 patients who harbored at least one paraophthalmic or superior hypophyseal aneurysm for which stent-assisted embolization was performed. Multiple aneurysms were identified in 20 (35%) patients; one patient had seven lesions. There was a striking female predominance, with 51 (89.5%) female patients and 6 (10.5%) male
Discussion
Paraophthalmic ICA aneurysms present unique challenges to both interventional and surgical therapies with respect to possible visual complications. In 1981, Ferguson and Drake (9) reported visual deficits in 32 of 100 surgical cases of carotid-ophthalmic aneurysms at the time of presentation. For the 29 patients for which follow-up visual results were available, improvement was seen in 12 patients, no change was seen in 11 patients, and worsening of symptoms was seen in 6 patients. In 1990, Day
Conclusions
Stent-assisted embolization of paraophthalmic and superior hypophyseal aneurysms does not appear to result in increased risk of visual complications compared with surgical or standard endovascular embolization without stent placement.
References (26)
- et al.
Carotid-ophthalmic aneurysms: visual abnormalities in 32 patients and the results of treatment
Surg Neurol
(1981) - et al.
Asymptomatic, unruptured carotid-ophthalmic artery aneurysms: angiographical differentiation of each type, operative results, and indications
Surg Neurol
(1997) Visual loss after neurosurgical repair of paraclinoid aneurysms
Ophthalmology
(1995)- et al.
Endovascular treatment of paraclinoid aneurysms
Surg Neurol
(2000) - et al.
Carotid-ophthalmic aneurysms
Surg Neurol
(1976) - et al.
The effect of vascular reconstruction device-assisted coiling on packing density, effective neck coverage, and angiographic outcome: an in vitro study
Neurosurgery
(2007) - et al.
Direct attack on carotid ophthalmic and large internal carotid aneurysms
Surg Neurol
(1977) - et al.
Aneurysm recurrence after treatment of paraclinoid/ophthalmic segment aneurysms—a treatment-modality assessment
Acta Neurochir (Wien)
(2005) Aneurysms of the ophthalmic segmentA clinical and anatomical analysis
J Neurosurg
(1990)- et al.
Clinoid and paraclinoid aneurysms: surgical anatomy, operative techniques, and outcome
Surg Neurol
(1999)
Postprocedure ischemic events after treatment of intracranial aneurysms with Guglielmi detachable coils
J Neurosurg
Carotid-ophthalmic aneurysms
J Neurosurg
Results, outcomes, and follow-up of remnants in the treatment of ophthalmic aneurysms: a 16-year experience of a combined neurosurgical and endovascular team
Neurosurgery
Cited by (30)
Effect on ophthalmic imaging findings of flow-diverting stent treatment covering the origin of the ophthalmic artery
2023, Photodiagnosis and Photodynamic TherapyApplication and reliability of the superselective balloon occlusion test in the treatment of complex cerebral artery aneurysms: A report of 12 cases
2019, Journal of Clinical NeuroscienceCitation Excerpt :Taken together with our findings, we conclude that it is feasible to perform PAS in the absence of neurologic deficits and positive imaging findings in the superselective BOT. The incidence rate of new visual deficits in OphA aneurysms treated surgically ranged from 4.8% to 7.5% [13]. The incidence rate of visual complications after endovascular coiling of OphA aneurysms is estimated to be 5% [14].
Central Retinal Artery Thromboembolism without Ophthalmic Artery Occlusion During Stent-Assisted Coil Embolization of Ophthalmic Artery Aneurysm
2019, World NeurosurgeryCitation Excerpt :Although endovascular treatment of these aneurysms has been proposed as an alternative to surgical clipping, the risk of impaired vision due to thromboembolism or occlusion of OphA after coil embolization is still a major concern.2,6,7 The incidence of visual complications following endovascular coil embolization of these aneurysms is estimated to be approximately 5%–10%.2,3,8,9 Table 1 showed visual outcomes of paraclinoid aneurysms after endovascular coil embolization.2,3,7,10-15
Vision Outcomes of Endovascular Treatment for Unruptured Ophthalmic Artery Aneurysms
2018, World NeurosurgeryCitation Excerpt :Endovascular treatment (EVT) has become the preferred treatment for OA aneurysms in most neurosurgical centers because microsurgical treatment of OA aneurysms is challenging because of several anatomic factors, such as the anterior clinoid process, perforating arteries, optic apparatus, and cavernous sinus. Despite accumulated experience and improved understanding of the devices for EVT, EVT for OA aneurysms still involves risks of impaired vision because of unexpected thromboembolism or OA occlusion after EVT, which is a major concern.1-3 Only a few studies have focused on the angiographic and clinical aspects of vision as a measure of therapeutic outcome.4,5
Visual Loss: Optic Neuropathies
2018, Liu, Volpe, and Galetta's Neuro-Ophthalmology: Diagnosis and ManagementVisual Loss: Disorders of the Chiasm
2018, Liu, Volpe, and Galetta's Neuro-Ophthalmology: Diagnosis and Management
Conflict of interest statement: M.J.A. is a device proctor and consultant for Boston Scientific Neurovascular.
published online 10 December 2011